Alar Pharmaceuticals Inc. (TPEX: 6785)
Taiwan
· Delayed Price · Currency is TWD 183.00
-8.00 (-4.19%)
Sep 10, 2024, 1:30 PM CST
Alar Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 469.27 | 469.27 | 0.8 | - | 0.6 | - | Upgrade
|
| Revenue Growth (YoY) | 58559.00% | 58559.00% | - | - | - | - | Upgrade
|
| Gross Profit | 469.27 | 469.27 | 0.8 | - | 0.6 | - | Upgrade
|
| Selling, General & Admin | 24.03 | 27.03 | 13.15 | 11.41 | 11.04 | 6.2 | Upgrade
|
| Research & Development | 63.27 | 56.71 | 34.18 | 81.89 | 160.33 | 55.19 | Upgrade
|
| Operating Expenses | 87.3 | 83.75 | 47.33 | 93.3 | 171.37 | 61.39 | Upgrade
|
| Operating Income | 381.98 | 385.53 | -46.53 | -93.3 | -170.77 | -61.39 | Upgrade
|
| Interest Expense | -0.04 | -0.06 | -0.02 | -0.02 | -0.03 | -0.04 | Upgrade
|
| Interest & Investment Income | 38.1 | 16.92 | 2.79 | 1.5 | 1.62 | 1.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 23.64 | -11.32 | 1.67 | 0.07 | 0.1 | 0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.11 | 0.04 | 9.55 | 27.52 | 26.28 | 2.8 | Upgrade
|
| EBT Excluding Unusual Items | 442.89 | 391.11 | -32.54 | -64.23 | -142.8 | -57.45 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -10.52 | Upgrade
|
| Pretax Income | 442.89 | 391.11 | -32.54 | -64.23 | -142.8 | -67.97 | Upgrade
|
| Income Tax Expense | 25.22 | 8.49 | -12.67 | - | - | - | Upgrade
|
| Net Income | 417.67 | 382.62 | -19.87 | -64.23 | -142.8 | -67.97 | Upgrade
|
| Net Income to Common | 417.67 | 382.62 | -19.87 | -64.23 | -142.8 | -67.97 | Upgrade
|
| Shares Outstanding (Basic) | 61 | 57 | 57 | 57 | 50 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 61 | 57 | 57 | 57 | 50 | 35 | Upgrade
|
| Shares Change (YoY) | 7.66% | 0.09% | - | 14.21% | 42.59% | 27.77% | Upgrade
|
| EPS (Basic) | 6.81 | 6.71 | -0.35 | -1.13 | -2.86 | -1.94 | Upgrade
|
| EPS (Diluted) | 6.81 | 6.71 | -0.35 | -1.13 | -2.86 | -1.94 | Upgrade
|
| Free Cash Flow | 250.74 | 397.23 | -34.09 | -65.05 | -142.31 | -69.44 | Upgrade
|
| Free Cash Flow Per Share | 4.09 | 6.96 | -0.60 | -1.14 | -2.85 | -1.98 | Upgrade
|
| Dividend Per Share | 1.500 | 1.500 | - | - | - | - | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | - | 100.00% | - | Upgrade
|
| Operating Margin | 81.40% | 82.15% | -5815.88% | - | -28460.83% | - | Upgrade
|
| Profit Margin | 89.00% | 81.53% | -2483.88% | - | -23799.50% | - | Upgrade
|
| Free Cash Flow Margin | 53.43% | 84.65% | -4260.75% | - | -23717.83% | - | Upgrade
|
| EBITDA | 384.33 | 387.58 | -44.16 | -90.82 | -168.78 | -59.09 | Upgrade
|
| EBITDA Margin | 81.90% | 82.59% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 2.35 | 2.05 | 2.36 | 2.48 | 1.99 | 2.3 | Upgrade
|
| EBIT | 381.98 | 385.53 | -46.53 | -93.3 | -170.77 | -61.39 | Upgrade
|
| EBIT Margin | 81.40% | 82.15% | - | - | - | - | Upgrade
|
| Effective Tax Rate | 5.69% | 2.17% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.